Could This Rare-Disease Drug Candidate Become a Blockbuster?

Could This Rare-Disease Drug Candidate Become a Blockbuster?

Submitted by admin on April 19, 2023 - 10:26am
Source: 
Motley Fool
News Tags: 
AstraZeneca
Ionis Pharmaceuticals
eplontersen
ATTR amyloidosis
Headline: 
Could This Rare-Disease Drug Candidate Become a Blockbuster?
snippet: 
  • AstraZeneca and Ionis recently shared promising phase 3 clinical trials for eplontersen.
  • If approved, the drug candidate could top $1 billion in annual sales -- split between the two companies.
  • AstraZeneca has an array other efforts, too, that make it an excellent pick for growth investors.

Do Not Allow Advertisers to Use My Personal information